



World Congress Insulin Resistance **DIABETES & CARDIOVASCULAR DISEASE** 

> **December 7–9, 2023 Hilton Universal City Hotel** Los Angeles, CA

> > DEMANOC

Exploring New Frontiers In Metabolism – Tomorrow's Clinical Science Today

CULTURE AN INCOME.



JOINTLY PROVIDED





**ADMINISTERED BY:** 



in

www.WCIR.org

@wcirdc #WCIRDC2023









### Ш 10 Ш U) m di li TT. m П

It is my pleasure to welcome you to the 21st Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.

The 21st Annual WCIRDC will be held on December 7–9, 2023, at the Hilton Universal City, Los Angeles. This CME/MOC conference will be available On-Demand for 90 days following the meeting.

Since its inception, the congress has become the premier global meeting dedicated to metabolism obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates clinical, translational and basic science. It offers an exclusive platform allowing professionals, clinicians and researchers to exchange ideas and collaborate

on emerging scientific and management concepts. The WCIRDC faculty consists of globally acclaimed experts who link research to clinical practice in a bench-to-bedside-to-bench approach which is unique to this state-of-the-art program.

We are proud to honor Professor Paul Zimmet, AO, MBBS, MD, PhD with the prestigious "Gerald Reaven Distinguished Leader in Insulin Resistance Award", recognizing his exceptional contributions to the field. Dr Zimmet's keynote lecture: Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective.

This year's conference will cover a wide range of topics including Lipidology, Cardiomyopathy & Heart Failure, Contemporary Management Of Obesity And Diabetes, The Multiple Faces Of Insulin Resistance, Women's Health State Of The Art Approach To Kidney, and Heart Disease, a joint session with the journal Metabolism; and much more encompassing the multifaceted realm of metabolic medicine. Distinguished experts are poised to unveil groundbreaking perspectives fostering an environment conducive to collaborative learning and professional growth.

Clinical workshops & meet-the-expert small groups sessions will provide attendees with a rare opportunity to personally

interact with esteemed leaders in an intimate setting. The Congress has a strong and highly successful abstracts program. Abstracts will be published in Metabolism Clinical and Experimental- IF 13.93 EIC Christos S. Mantzoros, MD, PhD, DSc.

The 21st WCIRDC will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and Industry Supported non-CME programs featuring important new scientific concepts with some of the world's best-known educators. I look forward to you attending this exciting conference on December 7–9, 2023, at Hilton Universal City Los Angeles, California. We hope to see you there.

Best regards,



# Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR

Paul S. Jellinger, MD

Samuel Klein, MD

Mikhail N. Kosiborod, MD

Ronald M. Krauss, MD

Norman E. Lepor, MD

Derek LeRoith, MD, PhD

Hollywood, FL

St. Louis, MO

Kansas City, MO

Berkeley, CA

Los Angeles, CA

New York, NY

Yehuda Handelsman, MD Chair Tarzana, CA

Richard N. Bergman, PhD Los Angeles, CA

Zachary T. Bloomgarden, MD New York, NY

Matthew J. Budoff, MD Los Angeles, CA

Sonia Caprio, MD New Haven, CT

Robert J. Chilton, DO San Antonio, TX

Kenneth Cusi, MD Gainesville, FL

Jaime A. Davidson, MD Dallas, TX

Ralph A. DeFronzo, MD San Antonio, TX

Vivian A. Fonseca, MD New Orleans, LA

W. Timothy Garvey, MD Birmingham, AL

Peter J. Grant, MD Leeds, UK

Jennifer B. Green, MD Durham, NC

George Grunberger, MD Bloomfield Hills, MI

Oceanside, CA

New Haven, CT

Chris K. Guerin, MD Philip Levy, MD Phoenix, AZ

Ania M. Jastreboff, MD, PhD Ildiko Lingvay, MD, MPH, MSCS Dallas, TX

Christos S. Mantzoros, MD, PhD Harvard, MA

Nikolaus Marx, MD Aachen, GER

Tracey L. McLaughlin, MD Stanford, CA

Christian W. Mende, MD La Jolla, CA

Erin D. Michos, MD, MHS Baltimore, MD

Jorge Plutzky, MD Boston, MA

**Richard E. Pratley, MD** Orlando, FL

Arun J. Sanyal, MD Richmond, VA

Philipp E. Scherer, PhD Dallas, TX

Alan R. Sinaiko, MD Minneapolis, MN

Bart Staels, PhD Lille, FR

Pam R. Taub, MD San Diego, CA

Muthiah Vaduganathan, MD, MPH Boston, MA

Matthew R. Weir, MD Baltimore, MD

Paul Zimmet, AO, PhD Melbourne, AUS

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 21st year, stands as a distinctive and vibrant multidisciplinary CME conference. Serving as the paramount global assembly dedicated to diabetes, obesity, lipids, cardiovascular-kidney, and liver diseases.

The Congress intricately weaves together basic research and clinical practice in pursuit of our guiding theme: Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.

Participants are able to earn up to 26.75 CME & ABIM-MOC credits.

The WCIRDC program features a unique convergence of basic and clinical science. For over two decades, it has convened physicians, clinicians, researchers, and other healthcare professionals into an international arena, crafting an exclusive program that seamlessly bridges the latest advancements from

The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney and the heart. The goal is to understand pathophysiology and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

- Discuss the effects of insulin resistance on the heart, kidney, and liver
- Describe the relationship between diabetes, obesity, kidney disease, and heart disease

# **PROGRAM DESCRIPTION**

bench-to-bedside-to-bench. Often resonating with the words, "I heard it first at the WCIRDC," the program provides an unparalleled opportunity for attendees to directly engage with distinguished global faculty, within an intimate setting, propelling explorations into the most current understanding of metabolic diseases and the unfolding emerging therapeutic approaches.

Since the seminal work of Dr. Gerald Reaven, crystallizing the interplay of insulin resistance, diabetes, obesity, and cardiovascular disease, the congress's scope has expanded. It now encompasses domains such as the kidney, liver, brain, bone, cancer, and beyond. The congress agenda includes dyslipidemia, atherosclerosis, hypertension, hypercoagulation, and inflammation. It also underscores the intricate interplay between Diabetes-Cardio-Renal and Metabolic Diseases. The program will cover updates on pharmaceutical interventions, including incretins- GLP1 ra and dual agonists, SGLT2/ & SGLT2/1i, PCSK9 i, MRA, bempedoic acid and IPE, will be illuminated. The aim is to foster an in-depth understanding of state-of-the-art pathophysiology, novel medical interventions, and the development of comprehensive clinical management strategies.

To bridge the gap between research and clinical practice, live Q&A and panel discussions will follow each session, exploring their implications in clinical scenarios. Enhanced interaction with faculty and fellow attendees will be facilitated through extended breaks and social events.

The Congress garners cutting-edge abstracts from both emerging researchers and renowned leaders across the globe. The best abstracts will be presented orally. There will be a key note presentation by professor Paul Zimmet, the recipient of the Gerald Reaven Distinguished Leader Award. Clinical workshops and meet the experts sessions allow for small groups learning and intimate face to face interaction with some of the best known leaders.

# **PROGRAM OBJECTIVES**

- Implement best practices for the prevention and management of CKD, HF, and CVD
- Describe the recommended uses of SGLT2 inhibitors for the treatment of HF
- Describe the contemporary role of SGLT2 inhibitors in CKD with and without diabetes as consistent with approved indications
- Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events
- Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease

- Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
- Evaluate the impact on clinical practice of new CVOTs in patients with diabetes and other cardiometabolic diseases
- Design therapeutic regimens for patients with multiple cardiorenal and metabolic disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
- Utilize technology to enhance the effectiveness of therapeutics

# **TARGET AUDIENCE**

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYNs, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.



# THURSDAY, DECEMBER 7

| 6:45 am  | Pre-Registration   |  |   |   |
|--|--|--|---|---|
| 7:00 am — 8:00 am  | EXHIBIT HALL OPENS   Coffee will   | be served  |   |   |
| 7:00 am – 7:45 am  | Breakfast Session<br>BMF-219: An Oral Menin Inhibitor in C<br>Supported by Biomea Fusion<br>Priyanka Somanath, PhD   | Non-CME Education<br>linical Development as a Short-term Therapy to<br>Thomas Butler, MS, MBA                              |   | duct Theater Hall<br>tes, Beta-cell Dysfunction<br>Juan Frias, MD         |
| 8:00 am — 8:15 am  | Welcome & Introduction   Pre-CME Que   | estions  |   | Yehuda Handelsman, MD   |
| Session 1<br>8:15 am – 9:30 am<br>8:15 am<br>8:35 am<br>8:55 am<br>9:15 am – 9:30 am | Endothelium and Cardiometer<br>Chairs: Vivian A. Fonseca, MD • Derek<br>The Effects of RYGB on Cholesterol and<br>Endothelial-Mesenchymal Transition in<br>The Role of SGLTx in ACS, A. Fib & Meter<br>Panel Discussion and Q&A  | LeRoith, MD, PhD<br>Bile Acid Metabolism in Humans<br>Cardiovascular Disease (EndMT)                                       |   | Bart Staels, PhD<br>Jorge Plutzky, MD<br>Robert J. Chilton, DO            |
| Session 2  | ASCVD Epidemiology, Patho  | ophysiology & Management   |   |   |
| 9:30 am — 10:45 am   | Chairs: Ronald M. Krauss, MD • Robert  | t J. Chilton, MD   |   |   |
| 9:30 am<br>9:50 am<br>10:10 am<br>10:30 am – 10:45 am<br>10:45 am – 11:15 am         | Importance of Cardiovascular Risk Assessment and Multiple Risk Factor Control in DiabetesNathan D. Wong, PhDCommon Molecular Mechanisms Drive Cardiometabolic and Vascular Diseases Outcomes- Clinical ImplicationsW. Timothy Garvey, MDThe Relationships Between HDL Dysfunction, Genetic Very Small LDL, CAC and Insulin ResistanceArthur S. Agatston, MDPanel Discussion and Q&AREFRESHMENT BREAK at the Exhibit Hall |  |   |   |
| Session 3  | Lipidology Toward 2024 - Panel Session   |  |   |   |
| 11:15 am – 12:10 pm  | Chairs: Erin D. Michos, MD, MHS • Chris K. Guerin, MD  |  |   |   |
| 11:15 am<br>12:10 pm   | The Role of the Mitochondrial/ER Axis in Cholesterol Metabolism and Statin Myopathy<br>Lp(a), CETP / BA-CLEAR / Very High HDL<br>Discussions and Q&A   |  |   | Ronald M. Krauss, MD<br>Seth S. Martin, MD, MHS<br>Arthur S. Agatston, MD |
| Session 4  | Concurrent Sessions: Meet  | the Experts  |   |   |
| 12:15 pm — 1:00 pm   |  | -  |   |   |
| 1:00 pm — 2:00 pm  | Ralph A. DeFronzo, MD<br>Vivian A. Fonseca, MD<br>Jennifer B. Green, MD<br>Yehuda Handelsman, MD<br>LUNCH BREAK  | Insulin Resistance — Intensive Management o<br>DCRM Risk Prediction<br>CKD Emerging Strategies<br>Technology in DM and CRM | of DM Sierra C/D (Lectur<br>Club<br>Hiro<br>Salon 6AB | re Hall)  |
| 1:10 pm — 1:55 pm  | Lunch Session<br>Jardiance® (empagliflozin) tablets: A<br>Supported by <mark>Boehringer Ingelheim</mark>   | Non-CME<br>Peer Review of the Latest Clinical Data and Do<br>—Lilly  | osing Recommendations                                 | duct Theater Hall<br>hristian Mende, MD                                   |

VERSA

# THURSDAY, DECEMBER 7 (Cont.)

| Session 5                                | Metabolic Science   |  |
|--|---|--|
| 2:00 pm – 2:50 pm                        | Chairs: Richard N. Bergman, PhD • Phillip E. Scherer, PhD   |  |
| 2:00 pm<br>2:20 pm<br>2:40 pm — 2:50 pm  | Genome- Proteome- Phenome & Mendelian Randomization Studies, Elucidating Novel Pathways and Treatments<br>Clinical Implication in Cardiometabolic Disorders<br>The Role of mRNA Modifications in the Regulation of Metabolism<br>Panel Discussion and Q&A | -<br>Christos S. Mantzoros, MD, PhD<br>Rohit Kulkarni, MD, PhD                             |
| <b>Session 6</b><br>2:50 pm – 3:40 pm    | The Future of HTN<br>Chairs: Pam R. Taub, MD • Chris W. Mende, MD   |  |
| 2:50 pm<br>3:10 pm<br>3:30 pm — 3:40 pm  | Refractory HTN and New Drugs & Procedures in the Future<br>Need for New Agents to Overcome Healthcare Disparity in Hypertension<br>Panel Discussion and Q&A   | Norman E. Lepor, MD<br>Keith C. Ferdinand, MD  |
| Session 7                                | DCRM 2.0 – Update and Global Transformation   |  |
| 3:40 pm — 4:10 pm                        | Chairs: Richard E. Pratley, MD • Matthew R. Weir, MD  |  |
| 3:40 pm<br>3:55 pm — 4:10 pm             | DCRM 2.0 - Diabetes CardioRenal & Metabolic Diseases- Update & Global<br>Panel Discussion and Q&A   | Yehuda Handelsman, MD  |
| 4:10 pm – 4:40 pm                        | REFRESHMENT BREAK at the Exhibit Hall   |  |
| Session 8                                | Insulin Resistance, Diabetes, and Beyond  |  |
| 5:00 pm – 6:35 pm                        | Chairs: Jennifer B. Green, MD • Jorge Plutzky, MD   |  |
| 4:40 pm<br>5:00 pm<br>5:20 pm<br>5:40 pm | Brain HDL and Alzheimer's Disease: Toward Therapeutic Applications<br>Pulmonary Disease in Diabetes- Another Final Frontier?<br>Contemporary Nomenclature of Fatty Liver Disease Impact on Diagnosis and Management<br>Vascular Aging in CKD              | Hussein Yassine, MD<br>Peter J. Grant, MD<br>Rohit Loomba, MD, MHSc<br>Matthew R. Weir, MD |
| 6:00pm<br>6:20 pm – 6:35 pm              | Management of Diabetes in Patients with Cancer Addressing Impact of Cancer Therapy<br>Overcoming Treatment Challenges: Management of Patients with Diabetes and Cancer<br>Panel Discussion and Q&A  | Emily J. Gallagher, MD, PhD  |

# 6:35pm – 7:30 pm WELCOME & POSTER RECEPTION AT EXHIBIT HALL

| 7:30 pm – 9:15 pm |              | Symposium   | Supported by AstraZeneca      |
|-------------------|--------------|---|-------------------------------|
|                   |              | he Trifecta of Diabetes, Heart and Kidney Diseases                                    |                               |
| Dramad.           | Chairs: Yehu | Jda Handelsman, MD ● Muthiah Vaduganathan, MD, MPH                                    |                               |
|                   | 7:30 pm      | Introduction & Pre-CME Questions  | Muthiah Vaduganathan, MD, MPH |
| Sand see 1        | 7:40 pm      | Early Intervention in Diabetes Addressing Pathophysiology in Preventing Comorbidities | Vivian A. Fonseca, MD         |
| THE               | 8:00 pm      | SGLT2i Effects Across The Spectrum of CKD And Multiple Populations                    | Peter Rossing, MD             |
|                   | 8:20 pm      | Impact of SGLT2i on HF Outcomes in Various Populations & The Range of LVEF            | Muthiah Vaduganathan, MD, MPH |
|                   | 8:40 pm      | Panel Discussion and Q&A: Changing the Trajectory of Heart Failure and CKD,           | <b>3</b> , ,                  |
|                   |              | Implementing Guidelines Directed Medical Therapy                                      |                               |
|                   |              | Panel: Vivian A. Fonseca, MD • Christian W. Mende, MD • Erin D. Michos, MD, MHS       |                               |
|                   |              | Peter Rossing, MD • Muthiah Vaduganathan, MD, MPH                                     |                               |
|                   |              | Moderator: Yehuda Handelsman, MD  |                               |
|                   | 9:10 pm      | Concluding Remarks & Post-CME Questions   |                               |
|                   | 9:15 pm      | Adjourn   |                               |



# FRIDAY, DECEMBER 8

| 7:00 am   | Registration   |  |   |           |
|---|--|--|---|-----------|
| 7:00 am — 8:00 am                                       | EXHIBIT HALL OPENS   |  |   |           |
| 7:00 am – 7:45 am                                       | Breakfast Session  | Non-CME  | Product Theater Hall  |           |
|   | Supported by <b>Bayer</b>  | ardiorenal Risk in CKD Associated with T2D   | Dharmesh S. Patel, MD, MBBS                                       |           |
| 8:00 am — 8:15 am                                       | Summary of Day 1 and Pre-CME   | Questions  | Zachary T. Bloomga  | rden, MD  |
| Session 9   | Women's Health   |  |   |           |
| 8:15 am — 9:05 am                                       | Chairs: Ania M. Jastreboff, MD •                                     | Pam R. Taub, MD  |   |           |
| 8:15 am<br>8:35 am<br>8:55 am — 9:05 am                 |  | Technology, and Cardiovascular Risk<br><sup>,</sup> Risk Associated with Pre, Newly Diagnosed, and Undiag  | Inosed- Diabetes Vivian A. For                                    |           |
| Session 10  | The Multiple Faces of In   |  |   |           |
| 9:05 am — 10:20 am                                      | Chairs: Ralph A. DeFronzo, MD •                                      |  |   |           |
| 9:05 am<br>9:25 am<br>9:45 am<br>10:05 am – 10:20 am    |  | e Body, Organ, Cellular, and Molecular Pathogenesis<br>I Energy Metabolism: Implications for Therapy<br>ınce or Obesity?   | Ralph A. DeFr<br>E. Dale Abel,<br>Samuel I                        |           |
| 10:20 am — 10:50 am                                     | REFRESHMENT BREAK at the   | Exhibit Hall   |   |           |
| Session 11  | <b>Progress in Pediatric O</b>                                       | besity and T2D: New and Advanced Trea  | tments  |           |
| 10:50 am — 12:05 pm                                     | Chairs: Sonia Caprio, MD • Alan                                      | R. Sinaiko, MD   |   |           |
| 10:50 am<br>11:10 am<br>11:30 am<br>11:50 am — 12:05 pm | Achieving Metabolic Homeostasis                                      | outh Onset Obesity and T2D: From Fantasy to Reality<br>in Youth with Obesity, Prediabetes/T2D and NAFLD, usin<br>for Youth with Obesity, Fatty Liver & T2D                         | Silva Arsla<br>ng Semaglutide 2, 4 mg. Sonia Ca<br>Rohit Kohli, N | aprio, MD |
| 12:05 pm — 1:05 pm                                      | LUNCH BREAK  |  |   |           |
| 12:15 pm — 1:00 pm                                      | Lunch Session<br>Mounjaro® (tirzepatide)<br>Supported by Lilly       | Non-CME  | Product Theater Hall<br>Steven Edelman, MD                        | 9         |
|   |  |  |   |           |
| Session 12  | Joint Session with Mete  | abolism  |   |           |
| 1:05 pm — 2:20 pm                                       | Chairs: Christos S. Mantzoros, MD                                    | ), PhD • Tracey L. McLaughlin, MD, MS  |   |           |
| 1:05 pm<br>1:25 pm<br>1:45 pm                           | From Physiology to Clinical Relev<br>Metabolic Surgery Important Rol | tors, Vascular Insulin Sensitivity in Cardiometabolic Disor<br>ance<br>e in the Comprehensive Management of Metabolic Diseas<br>2 Inhibitors: From Physiology to Clinical Outcomes | Michael A.  | -         |
| 2:05 pm — 2:20 pm                                       | to the Future in Heart Failure and<br>Panel Discussion and Q&A       |  | David Cherney, MI   | OCM, PhD  |

# FRIDAY, DECEMBER 8 (Cont.)

HOLLY WOOL

| C · 10   |   |  |  |  |
|--|---|--|--|--|
| Session 13   | Non-CME: A Glimpse into The Future - What's in the Pipeline?  |  |  |  |
| 2:20 pm – 3:20 pm<br>2:20 pm<br>2:35 pm<br>2:50 pm<br>3:05 pm – 3:20 pm<br>3:20 pm – 4:35 pm | Chairs: Ralph A. DeFronzo, MD • Christos S. Mantzoros, MD, PhD<br>Regeneron<br>Esperion<br>Corcept<br>Panel Discussion and Q&A<br><b>REFRESHMENT BREAK</b> at the Exhibit Hall  | Boaz Hirshberg, MD<br>Stephen L. Pinkosky, PhD<br>Joseph K. Belanoff, MD   |  |  |
| 3:40 pm – 4:25 pm  | Reception Session       Non-CME Education         The Evolving Cardiovascular-Renal-Metabolic Paradigm: How Can Healthcare Systems Better Match Science?         Supported by Boehringer Ingelheim         *Refreshments will be served    Pamela Kushner, MD   | Product Theater Hall Yehuda Handelsman, MD   |  |  |
| <b>Session 14</b><br>4:35 pm – 6:15 pm   | Contemporary Management of Diabetes<br>Chairs: George Grunberger, MD • Paul S. Jellinger, MD  |  |  |  |
| 4:35 pm<br>4:55 pm<br>5:15 pm<br>5:35 pm<br>5:55 pm – 6:15 pm                                | Molecular Mechanisms by Which Glucagon Regulates Hepatic Mitochondrial Oxidation<br>and Gluconeogenesis — Implications for Dual and Triple GLP-1 Analogs<br>Incretins in Diabetes- The New, the Newest and the Future<br>Application of CGM to Diabetes Prevention<br>Overcoming Clinical Inertia: The COORDINATE- Diabetes Example<br>Panel Discussion and Q&A   | Gerald I. Shulman, MD, PhD<br>Richard E. Pratley, MD<br>Tracey L. McLaughlin, MD, MS<br>Jennifer B. Green, MD      |  |  |
| 6:15 pm — 7:30 pm  | Dinner CME Symposium Sup  | ported by Lexicon Pharmaceuticals  |  |  |
|  | Breaking New Ground in Heart Failure Treatment         Chairs: Matthew J. Budoff, MD • Yehuda Handelsman, MD         6:15 pm       Introduction & Pre CME Questions         6:25 pm       Prevalence, Pathophysiology and Morbidities of Heart Failure         6:40 pm       Contemporary Approach to Management of Heart Failure         6:55 pm       Sotagliflozin: The Next Generation of Heart Failure Management         7:10 pm       Panel Discussion, Q&A, and Post-CME: Advancing the Care of Heart Failure- Relationship to CKD Panel: Matthew J. Budoff, MD • Stephen J. Greene, MD • Darren McGuire, MD, MHSc • Matthew Moderator: Yehuda Handelsman, MD         7:25 pm       Post-CME Questions & Concluding Remarks | Yehuda Handelsman, MD<br>Matthew J. Budoff, MD<br>Stephen J. Greene, MD<br>Darren McGuire, MD, MHSc<br>R .Weir, MD |  |  |
|  | 7:30 pm Adjourn   |  |  |  |
| 7:30pm - 9:00 pm   | Abstract Oral Presentation Cheese and Wine  |  |  |  |
| 7:30pm - 9:00 pm   |   | ry T., Bloomgarden, MD   |  |  |



### 8:00 am - 8:05 am Oral Abstract Award Presentation Zachary T. Bloomgarden, MD 8:05 am - 8:20 am Summary of Day 2 and Pre-CME Questions Zachary T. Bloomgarden, MD Session 15 Cardiomyopathy & Heart Failure - Panel Session Chairs: Nikolaus Marx, MD • Mikhail N. Kosiborod, MD 8:20 am - 10:00 am **Contemporary Approach to Cardiac Amyloidosis** Michelle M. Kittleson, MD, PhD Cardiomyopathy and Pregnancy Uri Elkayam, MD The Role of Diuretics in Heart Failure Stephen J. Greene, MD Management of Heart Failure: Bridging the Gap Between Evidence and Practice Gregg C. Fonarow, MD Discussions and Q&A 10:00 am **REFRESHMENT BREAK** 10:00 am - 10:10 am Session 16 **CVOT & Guidelines** 10:10 am - 11:00 am Chairs: Peter J. Grant, MD • Matthew R. Weir, MD 10:10 am CVOTs Update Mikhail N. Kosiborod, MD 2023 ESC Diabetes and Cardiovascular Disease Guidelines 10:30 am Nikolaus Marx, MD 10:50 am - 11:00 am Panel Discussion and Q&A Gerald Reaven Distinguished Leader in Insulin Resistance 2023 Award Session 17 11:00 am Award Presentation by Peter J. Grant, MD • Samuel Klein, MD 11:05 am Paul Zimmet, AO, MD, Ph Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective 11:35 am - 11:45 am Q&A 11:45 am - 12:45 pm LUNCH & CHECK-OUT BREAK Product Theater Hall 11:55 am - 12:40 pm Lunch Session Non-CME Innovation and Improved Outcomes with Abbott Diabetes Care Supported by Abbott George Grunberger, MD Fat Mass and Adipocyte Session 18 Chairs: Richard E. Pratley, MD • Bart Staels, PhD 12:45 pm - 1:35 pm 12:45 pm The Role of Relative Fat Mass- RFM vs. BMI Predicting T2D, Heart Failure and CVD Richard N. Bergman, PhD 1:05 pm GIP-R Action in the Adipocyte Philipp E. Scherer, PhD 1:25 pm – 1:35 pm Panel Discussion and Q&A

7:00 am - 7:45 am

8:20 am

7:00 am

Registration

**Breakfast Session Non-CME Education** Evolving Perspectives in Hyperglycemia Secondary to Hypercortisolism Supported by Corcept

**Mike Evans** 



Yehuda Handelsman, MD

SATURDAY, DECEMBER 9, 2023

Product Theater Hall



# SATURDAY, DECEMBER 9 (Cont.)

| Nutrient-Stimulated Hormone-Based Therapies for Obesity Treatment: Clinical Application and Pipeline<br>Diets, Calorie Restrictions vs Intermittent Fasting Addressing The Energy Balance Model<br>Weight and Weight Changes Impact on CV Risk<br>Discussions and Q&A: Does The Availability of Effective Pharmacotherapy To Treat Obesity Negates |   |   | Ania M. Jastreboff, MD, PhD<br>Eric Ravussin, PhD<br>Neha J. Pagidipati, MD, MPH  |
|--|---|---|---|
|  |   |   |   |
| REFRESHMENT BREAK  |   |   |   |
|  |   |   |   |
| Chairs: Paul Zimmet, AO, MD, PhD • Zo  | achary T. Bloomgarden, MD   |   |   |
| Diabetes Secondary to Pancreatitis<br>2023 Prevention and Management of T<br>Panel Discussion and Q&A  | TID- The New Reality  |   | Mark O. Goodarzi, MD, PhD<br>George Grunberger, MD  |
| ASCVD Imaging - Panel Session  | on  |   |   |
| Chairs: Matthew J. Budoff, MD • Norm   | an E. Lepor, MD   |   |   |
| CTA in Predicting Survival- the CONFIRM<br>Association of Coronary Artery Calcium  | N Registry<br>& Spine Bone Density  | Matthew J. Budoff,  | MD • Michael J. Blaha, MD, MPH  |
| Concurrent Sessions: Clinica   | l Workshop Wind   | e and Cheese  |   |
|  |   |   |   |
| Lipids<br>Diabetes<br>HTN/CKD  | Paul S. Jellinger, MD & Paul D. Rose<br>George Grunberger, MD<br>Christian W. Mende, MD   | enblit, MD, PhD Sierra<br>Club<br>Hiro  | C/D (Lecture Hall)  |
| Adjourn  |   |   |   |
|  | Chairs: Samuel Klein, MD • W. Timothy<br>Nutrient-Stimulated Hormone-Based Th<br>Diets, Calorie Restrictions vs Intermitter<br>Weight and Weight Changes Impact on<br>Discussions and Q&A: Does The Availab<br>The Need For The Other Treatment Opt<br><b>REFRESHMENT BREAK</b><br>Not All Diabetes – is Type 2<br>Chairs: Paul Zimmet, AO, MD, PhD • Ze<br>Diabetes Secondary to Pancreatitis<br>2023 Prevention and Management of<br>Panel Discussion and Q&A<br><b>ASCVD Imaging - Panel Sessio</b><br>Chairs: Matthew J. Budoff, MD • Norm<br>Imaging in Predicting Subacute Atheros<br>CTA in Predicting Subacute Atheros<br>CTA in Predicting Survival- the CONFIR<br>Association of Coronary Artery Calcium<br>Comparing Plaques in Patients with & M<br>Discussions and Q&A<br><b>Concurrent Sessions: Clinica</b><br>Lipids<br>Diabetes<br>HTN/CKD | Diets, Calorie Restrictions vs Intermittent Fasting Addressing The Energy Balance Matweight and Weight Changes Impact on CV Risk         Discussions and Q&A: Does The Availability of Effective Pharmacotherapy To Treat C         The Need For The Other Treatment Options? <b>REFRESHMENT BREAK</b> Not All Diabetes – is Type 2 DM         Chairs: Paul Zimmet, AO, MD, PhD • Zachary T. Bloomgarden, MD         Diabetes Secondary to Pancreatitis         2023 Prevention and Management of T1D- The New Reality         Panel Discussion and Q&A <b>ASCVD Imaging - Panel Session</b> Chairs: Matthew J. Budoff, MD • Norman E. Lepor, MD         Imaging in Predicting Subacute Atherosclerosis         CTA in Predicting Survival- the CONFIRM Registry         Association of Coronary Artery Calcium & Spine Bone Density         Comparing Plaques in Patients with & without Statins +/- DM         Discussions and Q&A         Concurrent Sessions: Clinical Workshop         Lipids       Paul S. Jellinger, MD & Paul D. Rose         Diabetes       George Grunberger, MD         HTN/CKD       Christian W. Mende, MD | Chairs: Samuel Klein, MD • W. Timothy Garvey, MD         Nutrient-Stimulated Hormone-Based Therapies for Obesity Treatment: Clinical Application and Pipeline         Diets, Calorie Restrictions vs Intermittent Fasting Addressing The Energy Balance Model         Weight and Weight Changes Impact on CV Risk         Discussions and Q&A: Does The Availability of Effective Pharmacotherapy To Treat Obesity Negates         The Need For The Other Treatment Options? <b>REFRESHMENT BREAK</b> Not All Diabetes - is Type 2 DM         Chairs: Paul Zimmet, AO, MD, PhD • Zachary T. Bloomgarden, MD         Diabetes Secondary to Pancreatitis         2023 Prevention and Management of T1D- The New Reality         Panel Discussion and Q&A <b>ASCVD Imaging - Panel Session</b> Chairs: Matthew J. Budoff, MD • Norman E. Lepor, MD         Imaging in Predicting Subacute Atherosclerosis         CTA in Predicting Subacute Athe |

# **21ST WCIRDC PROGRAM COMMITTEE**

Yehuda Handelsman, MD, Chair • Matthew Budoff, MD • Zachary Bloomgarden, MD, MACE • Sonia Caprio, MD

Robert Chilton, DO • Ralph DeFronzo, MD • Vivian Fonseca, MD • Tim Garvey, MD • Peter Grant, MD • Jennifer Green, MD

George Grunberger, MD • Chris Guerin, MD • Paul Jellinger, MD • Mikhail Kosiborod, MD

Ronald Krauss, MD • Norman Lepor, MD • Nikolaus Marx, MD • Tracy McLaughlin, MD, MS • Derek Leroith, MD, PhD

Christos Mantzoros, MD, PhD • Chris Mende, MD • Erin Michos, MD, MHS • Jorge Plutzky, MD • Richard Pratley, MD • Arun Sanyal, MD, MBBS

Phil Scherer, PhD • Alan Sinaiko, MD • Bart Staels, PhD • Pam Taub, MD • Matthew Weir, MD • Paul Zimmet, MD, AO, PhD • Renee Asp, BS



# Yehuda Handelsman, MD, Chair

FACP, FNLA, FASPC, FAHA, MACE Medical Director & Principal Investigator The Metabolic Institute of America Chair Scientific Advisory Board DCMi- Diabetes CardioRenal & Metabolism Institute Chair & Program Director 21st WCIRDC Tarzana, California



### E. Dale Abel, MD, PhD

William S. Adams Distinguished Professor of Medicine Chair and Executive Medical Director Department of Medicine David Geffen School of Medicine and UCLA Health Los Angeles, CA



## Arthur S. Agatston, MD, FACC, FSCCT

Chairman and CEO The Agatston Center for Preventive Medicine **Clinical Professor of Medicine** FIU Herbert Wertheim College of Medicine Clinical Associate Professor of Medicine. University of Miami Miller School of Medicine Medical Director of Wellness and Prevention Baptist Health South Florida Miami Beach, Florida



## Silva Arslanian, MD

Richard L. Day Professor of Pediatrics Pediatric Endocrinology Metabolism & Diabetes Mellitus University of Pittsburgh School of Medicine Director, Pediatric Clinical & Translational Research Center Scientific Director, Center for Pediatric Research in Obesity & Metabolism UPMC Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania



## Richard N. Bergman, PhD

Alfred Jay Firestein Chair in Diabetes Research Professor, Department of Biomedical Sciences and Medicine Cedars-Sinai Medical Center Director Diabetes and Obesity Wellness and **Research Center** Professor-in-Residence, UCLA Professor Emeritus USC



Los Angeles, California

# Michael Joseph Blaha, MD, MPH

Professor of Cardiology and Epidemiology, Johns Hopkins University School of Medicine Director of Clinical Research, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease Baltimore, Maryland



# **FACULTY 2023**

Zachary T. Bloomgarden, MD, MACE Clinical Professor, Department of Medicine Icahn School of Medicine at Mount Sinai Editor, The Journal of Diabetes New York, New York

# Matthew J. Budoff, MD, FACC, FAHA

Professor of Medicine David Geffen School of Medicine at UCLA Endowed Chair of Preventive Cardiology Lundauist Institute Program Director of Cardiac CT

Division of Cardiology Harbor-UCLA Medical Center Torrance, California





Professor of Medicine, University of Toronto Clinician Scientist, Division of Nephrology University Health Network Director, Renal Physiology Laboratory University Health Network Senior Scientist, Toronto General Hospital Research Institute Toronto, Ontario

# Robert J. Chilton, DO, FACP, FACC

FAHA, MACOI, FASCAI Professor of Medicine, Division of Cardiology Associate Program Director, Interventional Cardiology The University of Texas Health Science Center San Antonio, Texas

## Ralph A. DeFronzo, MD



Chief, Diabetes Division The University of Texas Health Science Center Deputy Director, Texas Diabetes Institute San Antonio, Texas

## Uri Elkavam, MD

Professor of Medicine (Cardiology) Obstetrics and Gynecology Director of the Maternal Cardiology Program Los Angeles, California

### Keith C. Ferdinand, MD, FACC, FAHA FASPC, FNLA

Gerald S. Berenson Chair in Preventative Cardiology Professor of Medicine, Tulane University School of Medicine New Orleans, Louisiana



### Gregg C. Fonarow, MD, FACC, FAHA, FHFSA

Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director, UCLA Preventative Cardiology Program Los Angeles, California

## Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Medical Center New Orleans, Louisiana

## Emily J. Gallagher, MD, PhD



Associate Professor, Division of Endocrinology Diabetes and Bone Disease Associate Program Director, Internal Medicine Residency Program,

Director ABIM Research Pathway for the Internal Medicine Residency Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

## W. Timothy Garvey, MD





## Mark O. Goodarzi, MD, PhD, FACP

Professor of Medicine Eris M. Field Chair, Diabetes Research Director, Endocrine Genetics Laboratory Cedars-Sinai Medical Center Los Angeles, California

## Peter J. Grant, MD, FRCP, FMedSci



Professor of Medicine and Diabetologist Honorary Consultant Physician Leeds Teachina Hospitals NHS Trust Division of Cardiovascular & Diabetes Research University of Leeds Leeds, United Kingdom





### Jennifer B. Green, MD

Professor of Medicine, Division of Endocrinology Duke University Medical Center Duke Clinical Research Institute Durham, North Carolina



### Stephen J. Greene, MD

Assistant Professor of Medicine (Cardiology) Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina



Chairman, Grunberger Diabetes Institute Clinical Professor, Internal Medicine and Molecular Medicine & Genetics Wayne State University School of Medicine Professor, Internal Medicine Oakland University William **Beaumont School of Medicine** Visiting Professor, Internal Medicine First Faculty of Medicine, Charles University, Prague, Czech Republic Bloomfield Hills, Michigan



### Chris K. Guerin, MD. FACE, FNLA

Medical Director, Diabetes Education Services and the **Diabetes Service Line** 

Past Chief, Division of Internal Medicine and Chair Department of Medicine, Tri-City Medical Center Founder, Advanced Metabolic Care and Research San Diego, California



## Michael A. Hill, PhD

Interim Director Dalton Cardiovascular Research Center Professor, Department of Medical Pharmacology and Physiology, MU School of Medicine The University of Missouri School of Medicine Columbia, Missouri

### Ania M. Jastreboff, MD, PhD

Associate Professor of Medicine & Pediatrics Endocrinology & Pediatric Endocrinology Director, Yale Obesity Research Center (Y-Weight) Co-Director, Yale Center for Weight Management Yale University School of Medicine New Haven, Connecticut



# Paul S. Jellinger, MD, MACE

Professor of Clinical Medicine Voluntary Faculty, University of Miami Miller School of Medicine The Center for Diabetes & Endocrine Care Hollywood, Florida

# Michelle M. Kittleson, MD, PhD



Professor of Medicine (Cardiology) Smidt Heart Institute Cedars-Sinai Medical Center Los Angeles, CA



Samuel Klein, MD Director. Center for Human Nutrition Chief Scientific Officer

**FACULTY 2023** 

Sansum Diabetes Research Institute Washington University School of Medicine Saint Louis, Missouri

Chief, Division of Gastroenterology, Hepatology

Associate Director, The Saban Research Institute

Professor of Medicine, University of Missouri

Inaugural recipient of the Ben McCallister, MD

Endowed Chair in Cardiovascular Research at

Senior Scientist and Director, Atherosclerosis Research

Children's Hospital Oakland Research Institute

Adjunct Professor, Department of Medicine, UCSF

Adjunct Professor, Department of Nutritional Sciences

Saint Luke's Health System.

Ronald M. Krauss, MD

University of California, Berkeley

Rohit Kulkarni, MD, PhD

Kansas City, Missouri

Berkeley, California

at Children's Hospital Los Angeles

### Rohit Kohli, MBBS, MS

and Nutrition



Los Angeles, California Mikhail N. Kosiborod MD, FACC, FAHA Vice President of Research, Saint Luke's Health System Executive Director, Cardiometabolic Center Alliance Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute









### Norman E Lepor, MD, FACC, FAHA



Founder and Director, National Heart Institute Past President, California Chapter, American College of Cardiology Clinical Professor of Medicine - Geffen School of Medicine-UCLA 2010-2023 Attending Cardiologist, Smidt Cedars-Sinai Heart Institute Los Angeles, CA

### Derek LeRoith, MD, PhD, FACP



Professor of Medicine, Director of Research Division of Endocrinology, Diabetes & Bone Disease Department of Medicine Icahn School of Medicine at Mt. Sinai New York, New York

### Rohit Loomba, MD, MHSc

Professor of Medicine Chief, Division of Gastroenterology and Hepatology Director, NAFLD Research Center UC San Diego School of Medicine University of California at San Diego UC San Diego Health San Diego, California



### Christos S. Mantzoros, MD, DSc, PhD h.c. mult.

Professor of Medicine, Harvard Medical School and Boston University School of Medicine Chief of Endocrinology, Diabetes, and Metabolism Boston VA Healthcare System Director of Human Nutrition Beth Israel Deaconess Medical Center Editor-in-Chief, Metabolism, Clinical & Experimental Harvard, Massachusetts



### Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Professor of Medicine (Cardiology) Johns Hopkins Hospital Johns Hopkins University School of Medicine Baltimore, Maryland

### Nikolaus Marx, MD, FESC, FAHA

Director of Medical Clinic I - Cardiology, Angiology and Internal Intensive Care Medicine University Hospital RWTH Aachen Professor of Medicine - Cardiology Internal Medicine and General Medicine **RWTH Aachen Universitv** Aachen, Germany

### Darren McGuire, MD, MHSc



Distinguished Teaching Professor of Medicine with Tenure Jere H. Mitchell, M.D. Distinguished Chair in Cardiovascular Science Division of Cardiology; Department of Internal Medicine University of Texas Southwestern Medical Center Lead Physician, Parkland Health Cardiology Clinics Deputy Editor, Circulation Dallas, Texas

### Tracey L. McLaughlin, MD, MS

Professor of Medicine, Division of Endocrinology Clinician Investigator Stanford University School of Medicine Stanford, California



Christian W. Mende, MD, FACP, FACN, FASN, FAHA **Clinical Professor of Medicine** University of California San Diego

La Jolla, California



# **FACULTY 2023**



### Erin D. Michos. MD. MHS FAHA, FACC, FASE, FASPC

Director of Women Cardiovascular Health Research Associate Director of Preventive Cardiology Division of Cardiology Johns Hopkins University School of Medicine Director, IMPACT Center at JHU Co-Editor in Chief American Journal of Preventive Cardiology Baltimore, Marvland



Associate Professor of Internal Medicine Catholic University, School of Medicine Chief, Division of Obesity and Related Disorders Policlinico A. Gemelli Hospital Rome, Italy Professor of Diabetes and Nutrition King's College London, London, UK



Associate Professor, Division of Cardiology Duke University School of Medicine Director, Duke Cardiometabolic Prevention Clinic Duke Clinical Research Institute Durham, North Carolina



## Jorge Plutzky, MD

Director, Preventive Cardiology, Brigham and Women's Hospital Boston, Massachusetts



## Richard E. Pratley, MD

Samuel F. Crockett Chair in Diabetes Research Medical Director, AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead AdventHealth Translational Research Institute Adjunct Professor of Medicine Johns Hopkins University School of Medicine Orlando, Florida

## Eric Ravussin, PhD

Director, Nutrition Obesity Research Center Douglas L. Gordon Chair in Diabetes and Metabolism Boyd Professor and Associate Executive Director for Clinical Science

Metabolic Chambers Human Translational Physiology Pennington Biomedical Research Center Louisiana State University Baton Rouge, Lousiana



## Paul D. Rosenblit, MD, PhD, FACE, FNLA

Clinical Professor, Medicine Division of Endocrinology, Diabetes, Metabolism University of California, Irvine School of Medicine Director, & Site Principal Investigator Diabetes / Lipid Management & Research Center Huntington Beach, California





Herley, Denmark

# Philipp E. Scherer, PhD



Professor, Department of Internal Medicine Gifford O. Touchstone Jr. and Randolph G. Touchstone Distinguished Chair in Diabetes Research Director, Touchstone Diabetes Center The University of Texas, Southwestern Medical Center Dallas, Texas

## Gerald I. Shulman, MD, PhD, MACP, MACE, FRCP

George R. Cowgill Professor of Medicine (Endocrinology) Professor of Medicine and Cellular & Molecular Physiology Co-Director Yale Diabetes Research Center Investigator Emeritus, Howard Hughes Medical Institute New Haven, Connecticut

## Alan R. Sinaiko, MD




Professor Emeritus, Department of Pediatrics Division of Pediatric Nephrology University of Minnesota Medical School Pediatrics and Division of Epidemiology School of Public Health Minneapolis, Minnesota

# Bart Staels, PhD

Co-founder of GENFIT Chairman of the Scientific Advisory Board Full Professor, Faculty of Pharmacy, University de Lille Director, Inserm UMR1011, Institut Pasteur de Lille Lille. France

## Pam R. Taub, MD, FACC, FASPC



Professor of Medicine Division of Cardiovascular Medicine UC San Dieao Health System La Jolla, California

## Muthiah Vaduganathan, MD, MPH, FACC, FHFA

Cardiologist and Clinical Trialist Brigham and Women's Hospital and Harvard Medical School Co-director, Center for Cardiometabolic Implementation Science Boston, Massachusetts

# Matthew R. Weir, MD



Professor and Chief Division of Nephrology Department of Medicine University of Maryland School of Medicine Baltimore, Maryland



### Nathan D. Wong, PhD, MPH, FACC FAHA, FNLA, MASPC

Professor and Director Heart Disease Prevention Program Division of Cardiology, University of California, Irvine Past President, American Society for Preventive Cardioloav Irvine, California

### Hussein Yassine, MD



## Paul Zimmet, AO, MD, PhD, FRACP, FRCP, FTSE



Professor of Diabetes, Monash University Honorary President, International Diabetes Federation 2018 Victoria Senior Australian of the Year Co-Director, The Sagol Center for Epigenetics of Metabolism and Ageing, Tel Aviv Medical Center, Israel Doctor of Laws, Honoris Causa (Monash) Doctor Philosophiae Honoris Causa (Tel Aviv) Honoris Causa Doctoris (Complutense University (Madrid) Doctor of the University, Honoris Causa (Adelaide) Doctor of Philosophy, Umea University (Sweden) Melbourne, Australia

## (Pipeline Speaker)

Boaz Hirshberg, MD Senior Vice President, Clinical Sciences General Medicine, Regeneron Tarrytown, New York

## (Pipeline Speaker)



Stephen Pinkosky, PhD Vice President, Head of Discovery and Early Development, Esperion Arbor, Michigan



12



# **REGISTRATION INFORMATION**

# www.wcir.org/registration

# Email info@tmioa.com To register by phone (818) 342-1889

All 21st WCIRDC participants must be vaccinated in order to attend the live in person meeting. For further information please contact info@tmioa.com

# **CME Accreditation:**

For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

# AMA PRA Designation Statement:

PESI Inc. has designated this Live activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

# **MOC Points with ABIM:**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points 26.75

# **International CME:**

International Physicians are formally eligible for AMA PRA Category 1 Credit™.

# **Physician Assistants:**

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

# Nurses:

For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

# **Pharmacists**

For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

# CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours 26.75

# **Registered Dietitians**

For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

# **Satisfactory Completion for Credits**

All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity. \* For Physicians to have credits recorded to ACCME PARs for licensing and certification board records, physicians must provide: 1) State of licensure, 2) license ID #, 3) Birthdate - month and day, and 4) ABIM #.

MANDI

# Enduring/ On-Demand CME Activity

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

# **AMA PRA Designation Statement**

PESI Inc. has designated this Enduring activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available online at www.wcir.org from December 10, 2023 through March 10, 2024.



# **2023 PARTNERS**

# **ASSOCIATED ORGANIZATIONS**

# **Associated Organizations**

- American Society of Endocrine Physician Assistants (ASEPA)
- American Society of Preventive Oncology (ASPO)
- Association of Diabetes Care and Education Specialists (ADCES)
- Endocrine Nurses Society (ENS)
- International Federation for Surgery of Obesity & Metabolic Disorders (IFSO)

- Israel Endocrine Society (IES)
- Point of Care Network (POCN)
- Society for Endocrinology (SFE)
- Societa Italiana Endocrinologia (SIE)
- World Obesity Federation (WOF)
- National Kidney Foundation of America (NKFA)
- Korean Heart Rhythm Society (KHRS)

# **Premier Media Partners**

- Metabolism (Elsevier)
- Healio Cardiology Today & Endocrine Today
- Closed Concerns
- American Journal of Cardiology (Elsevier)
- American Journal of Managed Care (MJH Life Sciences)
- HCPLive Network (MJH Life Sciences)

# **MEDIA PARTNERS**

# **Media Partners**

- CN1699 Media
- ConferenceLocate.com
- Connected Health
- Diabetes and Vascular Research (Sage)
- Diabetes in Control
- Elsevier
- Endocrine Web
- Endocrinology Network
- Family Heart Foundation
- Frontiers in Clinical Diabetes and Healthcare
- Journal of Diabetes
- Metabolism and Target Organ Damage
- MDPI
- MedTech
- MEDTube
- Nutrients Open Access Journal

- OAE Publishing Inc.
- PharmaVoice
- Physician's Weekly
- Practical Cardiology
- Society for Vascular Surgery
- Strategic AJMC Alliance (MJH Life Sciences)
- Strategic Endocrinology Network Alliance (MJH Life Sciences)
- Strategic Practical Cardiology Alliance (MJH Life Sciences)
- The Journal of Cardiovascular Aging
- The Journal of Cardiovascular Development and Disease
- The Journal of Clinical Medicine
- VenueDir
- VP Vessel Plus

# Premier Associated Organizations

- Clinical Association of California Endocrinologists (CACE)
- California Chapter American College of Cardiology (CAACC)
- American Society for Preventive Cardiology (ASPC)

THE INTERNATIONAL COMMITTEE FOR INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES

DELY WOIL

# EDUCATIONAL GRANT ASTRAZENECA LEXICON PHARMACEUTICALS BAYER

# **BOEHRINGER INGELHEIM-LILLY**

# AMGEN

**ESPERION THERAPEUTICS** 





# SAVE THE DATE | December 12-14, 2024



# Hilton Universal 555 Universal Hollywood Dr, Universal City, CA 91608

wcir.org

in

@wcirdc

MEEF \*PESI CME MOC STMICA

# SUPPORT · REGISTRATION · ACCOMMODATIONS · EXHIBITION 818.342.1889 | 818.342.1538 | info@tmioa.com www.wcir.org

Metabolic Endocrine Education Foundation (MEEF) 638 Lindero Canyon Dr Suite #380 Oak Park, CA 91377